---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-069662"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2024-08-15T23:59:59+00:00"
generated_at: "2026-05-31T09:11:47.028256+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# ARCA biopharma sells legacy Gencaro and rNAPc2 assets to Genvara for $300K

## Summary
- ARCA entered Asset Purchase Agreement with Genvara Biopharma to sell all rights in Gencaro (bucindolol) for atrial fibrillation and rNAPc2 (AB201) for COVID-19.
- Total cash consideration is $300,000, payable pre-closing and held in escrow until the Closing.
- Closing of asset sale is automatic immediately following the First Merger (Oruka merger).
- Buyer Genvara is controlled by Dr. Michael Bristow, ARCA's former President/CEO.
- The asset sale is a condition to the broader reverse merger with Oruka Therapeutics.

## SEC filing metadata
- accession: 0001213900-24-069662
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2024-08-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000121390024069662/0001213900-24-069662-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000121390024069662/ea0211472-8k425_arcabio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-069662
- JSON: https://secwatch.observer/filing/0001213900-24-069662.json
- Plain text: https://secwatch.observer/filing/0001213900-24-069662.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.